Download the App!
show episodes
 
We explore news and insights from global healthcare markets, advising how pharma and medtech need to respond and adapt their market access strategy in light of the latest insights from our experts. The podcast features insights from our associates across global healthcare, along with thought leadership from the market access and HEOR experts at Petauri Evidence.
  continue reading
 
Loading …
show series
 
Send us a text What do global market access teams need to know about the US market? What do US payers expect to hear from Pharma and Medtech companies? What kind of value messaging resonates in the US? How do you prepare for launch in a market as diverse as the US? In this Global Whispers episode, Louise Maddison (Senior Consultant – Global Market …
  continue reading
 
Send us a text Discover how health economics can support successful Medical Device launch, proposition development, and market access This episode offers an insightful journey into the world of medical device market access. Specialists from our health economics and market access teams explore the hidden challenges faced by medical devices companies…
  continue reading
 
Send us a text What clinical and economic evidence do US payers prefer to drive formulary decisions? How can you optimise your chances of preferential access in the US with the right evidence? How should evidence be generated, synthesised, and presented for the US market? In this episode, Clare Foy (Director – Global Market Access, Mtech Access) in…
  continue reading
 
Send us a text How can real-world evidence (RWE) support health technology assessment (HTA)? Can real-world data (RWD) supplement clinical data? How can RWE be used to solve common challenges with treatment comparison? Here, Mtech Access are joined by experts from Arcturis and Delta Hat. Dan Howard (Associate Director – Health Economics, Mtech Acce…
  continue reading
 
Send us a text How is the NHS preparing for winter? Which challenges are the most pressing for NHS decision-makers? How can industry best engage and support NHS decision-makers in the next few months? In August, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Access) was joined by Jo Turl (Former Director of Commissioning, Devon …
  continue reading
 
Send us a text Are you a global market access lead looking to understand the challenges faced by your UK affiliates? Or do you work at a national level with responsibility for bringing a new health technology to the NHS in England? In July 2024, Global Whispers and NHS Whispers came together, to bring you an overarching view of what it takes to acc…
  continue reading
 
Send us a text What can we expect to see in primary care in the NHS given recent policy announcements and ongoing uncertainty? What does the new GP Contract tell us about the future of primary care? What are the biggest challenges facing primary care in 2024–25? In this webinar, Karen Cooper (Senior Consultant – NHS Insight & Interaction, Mtech Acc…
  continue reading
 
Send us a text Discover how data visualisation dashboards can aid field teams in market access discussions with customers. Healthcare leaders look to real-world data (RWD) to inform decisions. Field teams presenting decision-makers with RWD within a well-designed, easy-to-use visualisation can build a case for change, while positioning themselves a…
  continue reading
 
Send us a text What do you need to know about the market access and reimbursement landscape in Canada? What changes can we expect at the Canadian Agency for Drugs and Technologies in Health (CADTH) in 2024/2025? In this webinar, Clare Foy (Director – Global Market Access, Mtech Access) interviewed Don Husereau (Adjunct Professor of Medicine, The Un…
  continue reading
 
Send us a text Where will you be launching your new orphan medicine? You may be confident that your Global market access strategy will support access in key launch markets like the UK, the EU4 and the US, but have you thought about other markets? Have you looked at the reimbursement requirements for rare disease products in the Nordic markets? Have…
  continue reading
 
Send us a text Which decisions are made at Region level in the NHS in England? How do finances and funding work at this level? And how can industry best support and engage with Region leaders? We sit down with guest speaker Richard Smale (Interim Director of System Co-ordination, NHS England [NHSE] – South West) for an all-encompassing discussion t…
  continue reading
 
Send us a text What do we know about plans and policy for 2024/25? As the expected central operating plan had not materialised (at time of recording), and with a general election and a potential Labour government on the horizon, how can NHS and industry drive forward improvements and innovation? Host Robert Hull (Senior Consultant – NHS Insight & I…
  continue reading
 
Send us a text What is health economic evaluation and which modelling approaches can be used to support market access activities? In this episode, our expert health economists explain the key strengths and limitations of the most common health economic modelling classifications and structures. Here, Hannah Gillies (Consultant – Health Economics) an…
  continue reading
 
Send us a text Here, our experts explore evidence strategies for medical devices, diagnostics and digital health technologies. Have you established the clinical and economic value of your medical device, diagnostic or digital technology? Do you have the evidence required to support your value proposition? Would a health technology assessment (HTA) …
  continue reading
 
Send us a text How can you ensure your product is set up for success from early clinical trials right through to launch and commercialisation? In this Global Whispers webinar we explore best practice commercialisation strategy for healthcare products launching in the US market. Clare Foy (Director – Global Market Access, Mtech Access) speaks to Jan…
  continue reading
 
Send us a text What’s happening with specialised commissioning in the NHS? How likely is a delay in delegation to integrated care boards (ICBs)? How and what should Pharma and Medtech plan for amidst all this uncertainty? Malcolm Qualie (former Medicines Lead for Specialised Services, NHS England) speaks to David Thorne (Principal Associate, Mtech …
  continue reading
 
Send us a text What does it take to run a truly patient-centric integrated health system? What does the Welsh journey with integration tell us about the future for England? Paul Mears (CEO, Cwm Taf Morgannwg University Health Board) joins Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) to explore the integrated care model …
  continue reading
 
Send us a text Clare Foy (Director – Global Market Access, Mtech Access) speaks to Italian market access expert Prof. Fabrizio Gianfrate (Professor of Health Economics and Outcomes Research [HEOR] and Ex-Payer) about the market access landscape in Italy, particularly regarding changes at the Agenzia Italiana del Farmaco (AIFA). We explore: - The na…
  continue reading
 
Send us a text Dr Farzana Hussain (GP Principal, The Project Surgery) and Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) explore the unmet needs of Primary Care Networks (PCNs) and how industry can best support primary care leaders and GPs as we head into winter, 2024 and beyond. Former ‘GP of the year’ and strategic influ…
  continue reading
 
Send us a text How can our community support NHS leaders to deliver a data-led, people-centric health service? Dr Mark Davies (Global Chief Health Officer, IBM) joins Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) to explore the power of data, the role of community and how the health and life sciences ecosystem can support…
  continue reading
 
Send us a text How is Artificial Intelligence being used in the development of new medicines? What role can AI currently play in clinical trials? Where can AI bridge gaps and solve challenges? What could this mean for the future of market access? In this webinar, Dr George Magrath explains how his team at Lexitas are using AI in clinical trials in …
  continue reading
 
Send us a text How is the UK political landscape evolving and what does this mean for Health Technology and Medical Device innovators? Robert Hull (Senior Consultant – NHS Insight & Interaction, Mtech Access) speaks to William Lee (Head of Policy and Compliance, British Healthcare Trades Association [BHTA]) about health policy, regulation and its i…
  continue reading
 
Send us a text Here we explore market access challenges in Germany, Austria and Switzerland. Clare Foy (Global Market Access Director – Mtech Access) speaks to Dr Stefan Walzer (CEO, President & Founder at MArS Market Access & Pricing Strategy GmbH) about the challenges and opportunities for reimbursement in the German-speaking markets. Clare and S…
  continue reading
 
Send us a text How are nursing professionals supporting the digital evolution in UK healthcare? How can new technologies be leveraged by front-line clinical teams to support improved patient care? And how can Medtech, Digital and Biotech innovators collaborate with the front-line nursing teams in the NHS to drive transformation? Prof. Phil Richards…
  continue reading
 
Send us a text In this Global Whispers webinar we explore market access for digital therapeutics. Clare Foy (Global Market Access Director – Mtech Access) speaks to Shefali Shah (Global VP, Market Value and Commercial Effectiveness – MindMaze) about the challenges and opportunities for digital therapies to gain market access and ultimately improve …
  continue reading
 
Send us a text What does it take to bring a cannabinoid pharmaceutical to market? We were delighted to welcome Michael Sassano (CEO – SOMAÍ Pharmaceuticals) as the first guest on our new Global Whispers webinar series. Michael shared with us his company’s experiences bringing new products to market, the challenges SOMAÍ Pharmaceuticals have faced a…
  continue reading
 
Send us a text How will changes to the structure of primary care impact decision making? How is the relationship between Integrated Care Boards (ICBs) and primary care stakeholders evolving? How will funding flows be impacted? Prof. Phil Richardson (Chair and Chief Innovation Officer, Mtech Access) is joined by Tim Goodson (Executive Officer, Dorse…
  continue reading
 
Send us a text Is data the key to transforming healthcare systems and patient care? What are the top priorities for digital transformation leaders in the NHS? How can Pharma and Medtech companies partner with the NHS to share data, transform services, and find smarter, faster way to improve patient care? Prof. Phil Richardson (Chair and Chief Innov…
  continue reading
 
Send us a text How and where can innovation drive improvements in care and deliver better health for the population? How is the NHS looking to collaborate with key partners across industry and academia? What innovations are set to transform care? What role do Academic Health Science Networks (AHSNs) play and how can partners best engage with them? …
  continue reading
 
Send us a text Will NHS leaders, as part of an Integrated Care System (ICS), make conscious decisions to drive economic and social change? What social and economic value do ICSs offer the wider population they serve? How will industry support ICSs to deliver population-based health and social benefits? Prof Phil Richardson (Chair and Chief Innovati…
  continue reading
 
Send us a text The proposed new NHSE systems for specialised commissioning are arguably the highest risk of all current dynamics, both for the NHS and for suppliers. Key aspects or policy have been published in ways that are hard to access and even harder to interpret. Here, we gather an expert panel to discuss what proposed new NHSE systems for sp…
  continue reading
 
Send us a text With so many patients left waiting for NHS care, what will the long-term impact be? How can Pharma and Medtech support the NHS with systematic challenges, like waiting? Where can industry work with the NHS to improve patient flow to get people appropriate treatment sooner and limit the harm caused by waiting? Prof Phil Richardson (ne…
  continue reading
 
Send us a text How is the NHS balancing competing challenges as we head through integration and towards winter? How are priorities set and what does system planning look like in primary care? Dr Alex Degan (Primary Care Medical Director, Devon Integrated Care System [ICS]) joins Tom Clarke (Director, Mtech Access) to explore all this and more. In t…
  continue reading
 
Send us a text On 1st July we saw the introduction of legislation for Integrated Care Systems (ICSs) in the NHS. In the weeks since, what has changed for healthcare leaders, practitioners and patients? What are the key priorities for NHS decision-makers and what is getting in the way of change? How can Pharma and Medtech support their NHS customers…
  continue reading
 
Send us a text What roles and responsibilities do Clinical Pharmacists have in the NHS? How can Pharma and Medtech engage Clinical Pharmacists, and how can industry best support these new decision-makers? Tom Clarke (Director, Mtech Access) explores all this and more with Tom Kallis (Senior Clinical Pharmacist, East Cornwall PCN). They explore the …
  continue reading
 
Send us a text As the NHS takes steps towards a more integrated future, how are systems and care pathways transforming? How is change being implemented, and what does this look like in reality for local systems and populations? Tom Clarke (Director, Mtech Access) explores all this and more with Debbie Morgan, (Director of Service Improvement and Tr…
  continue reading
 
Send us a text Our experts in health economics, value communication, design and digital discuss how to craft digital payer value communication tools to meet the needs of internal stakeholders, including market access teams and KAMs, and healthcare customers. What does a best-in-class value communication tool look like in 2022? What are the key cons…
  continue reading
 
Send us a text What does population health management mean for the NHS, for patients, and for industry? How will the NHS translate population health management into impactful service change and what will this look like for patients? Tom Clarke (Director, Mtech Access) explores all this and more with guest speaker Dr Steven Laitner (GP, Parkbury Hou…
  continue reading
 
Send us a text What does the ‘2022/23 priorities and operational planning guidance’ document mean for the NHS, for Integrated Care System (ICS) development and for an NHS workforce still battling COVID? How realistic and achievable are the priorities set out, and how can Pharma and Medtech best help NHS leaders to achieve these goals? Caroline Dawe…
  continue reading
 
Send us a text Pharma and Medtech professionals put questions to our panel of NHS associates as we reflected on the operational, structural, and clinical challenges the NHS has faced in 2021 and how Pharma and Medtech can best support the NHS in 2022. We were joined by some of Mtech Access’s closest and most insightful friends: - David Thorne (Dire…
  continue reading
 
Send us a text How will medicines be valued in the newly integrated world of the NHS? What are the risks and benefits of a single national formulary? What else is changing? And what does this mean for market access? Ellen Rule (Programme Director of the Gloucestershire Integrated Care System [ICS] and Director of Transformation and Service Redesign…
  continue reading
 
Send us a text We explore the challenges facing orphan medicines and other innovative rare disease treatments looking to achieve market access in Europe. Orphan medicines and rare disease treatments are faced with a complex, ever-changing market landscape. These treatments also face unique tactical challenges on the route to securing market access.…
  continue reading
 
Send us a text How are healthcare systems looking differently at their population to deliver better care and what does this mean for future decision-making? How might the NHS re-imagine the hospital? What benefits can we expect from novel technologies, and can the NHS develop system resilience to improve healthcare outcomes? Dr Phil Webb (Chief Exe…
  continue reading
 
Send us a text How can the NHS address health inequalities through innovation? How can new health technologies help improve population health? How can Pharma, Medtech and the wider life sciences industry support the NHS with these goals? And what does the NHS’ ambitions in this area mean for your market access strategy? Jon Siddall (Chief Executive…
  continue reading
 
Send us a text What role do Ambulance Trusts play in the success of the wider NHS? How might urgent and community care evolve as we head to integration as part of a joined-up system? How will an integrated ambulance service support system redesign to keep people out of hospital, and provide more proactive care to those who need it most? Helen Ray (…
  continue reading
 
Send us a text Population health management is often talked about in top-down terms, but how seriously will the needs of individuals be taken as systems develop? How will personal needs inform care delivery? Why will the patient voice play a very different role in the NHS of the future? Steph Edusei (Chief Executive of St Oswald’s Hospice) joins To…
  continue reading
 
Send us a text What will a ‘Place’ look like? What will this new layer of the NHS mean in practice and what decision-making powers will Place leaders have? As the NHS starts its journey towards an integrated future, Dr Steven Michael OBE (Chair of East Cheshire Partnership) joins Tom Clarke (Director, Mtech Access) to talk ‘Place’, ‘Partnership’, ’…
  continue reading
 
Send us a text Are you looking to launch a new medical technology, medical or diagnostic device in the UK, Europe or North America? Would you like to know how health economic modelling could support your market access journey? In this episode, converted from a recent live webinar, Calum Jones (Consultant Health Economist) and Nick Swart (Senior Hea…
  continue reading
 
Send us a text What changes can we expect to pharmacy, medicines management, and specialised commissioning in the new NHS? Professor Inderjit Singh (Chief Pharmacist at University Hospitals Birmingham) joins Tom Clarke (Director, Mtech Access) to explore all this and more. Professor Singh is one of the leading pharmacists in today’s NHS and is curr…
  continue reading
 
Send us a text Are you wondering what integrated care will look like when the Health and Care White Paper proposals become a reality? Tom Clarke interviews Dr John Ribchester about what the proposals means in practice for clinicians, for patients and for the life sciences industry. Dr Ribchester is a GP and Clinical Director of Whitstable Primary C…
  continue reading
 
Loading …

Quick Reference Guide

Listen to this show while you explore
Play